Groups | TC, mmol/l | HDL-C, mmol/l | TC/HDL-C Ratio | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
t = 0 Weeks | t = 52 Weeks | % Change (95% CI) | p | t = 0 Weeks | t = 52 Weeks | % Change (95% CI) | p | t = 0 Weeks | t = 52 Weeks | % Change (95% CI) | p | |
Group 1, low-low CRP | 5.10 (0.97) | 5.18 (0.94) | +1.6 (−1.8–4.9) | 0.328 | 1.34 (0.45) | 1.37 (0.47) | +2.2 (−1.5–6.7) | 0.267 | 4.18 (1.50) | 4.20 (1.67) | +0.5 (−5.6–6.2) | 0.881 |
Group 2, high-low CRP | 4.85 (0.91) | 5.25 (0.96)* | +8.2 (3.5–13.0)* | 0.001 | 1.33 (0.39) | 1.44 (0.42)* | +8.3 (2.3–14.3)* | 0.011 | 3.92 (1.34) | 3.96 (1.39) | +1.0 (−4.8–6.9) | 0.744 |
Group 3, high-high CRP | 4.70 (0.87) | 4.80 (1.05) | +2.1 (−11.3–15.5) | 0.736 | 1.32 (0.36) | 1.29 (0.36) | −2.3 (−9.1–3.8) | 0.389 | 3.74 (1.31) | 3.88 (1.24) | +3.7 (−5.9–13.4) | 0.424 |
↵* p < 0.05 compared with baseline. TNF-α: tumor necrosis factor-α; CRP: C-reactive protein; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; Group 1, n = 78: patients with CRP levels below 10 mg/l throughout the treatment period; Group 2, n = 54: patients in whom CRP levels dropped from ≥ 10 mg/l to below 10 mg/l; Group 3, n = 14: patients in whom CRP levels did not drop below 10 mg/l upon treatment.